Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...
Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...
Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...
Weight loss drugs are incredibly sought-after, but they’re also often difficult to obtain due to limited insurance coverage ...
Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...
Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...
In a study of around 228,000 people in Sweden who had alcohol use disorder, researchers found that people who were taking a ...
Pemvidutide is a promising GLP-1/glucagon dual receptor agonist that focuses on fundamental metabolic processes to stimulate ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide ( Ozempic, Wegovy) could curb drinking ...
Ro details dietary choices that may help Wegovy's capacity to regulate appetite and foster a healthier weight as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback